Hemispherx Biopharma (HEB)
Hemispherx Biopharma Times Interest Earned TTM: -357.22
View HEB Times Interest Earned TTM with YCharts Pro.
Access these YCharts Pro features:
Export any data you want
Save any chart as an image
Utilize advanced screener power
View 30 years of financial history
over 90 advanced calculations
Enjoy an advertising free experience
HEB Times Interest Earned TTM Rankings
| Overall | 2nd percentile | 2979 of 3051 |
| Sector | 9th percentile | 318 of 352 in Healthcare |
| Industry | 19th percentile | 79 of 98 in Biotechnology |
HEB Times Interest Earned TTM Range, Past 5 Years
| Minimum | -3095 | Sep 2010 |
| Maximum | 155.89 | Jun 2009 |
| Average | -531.35 |
About Times Interest Earned (TTM)
Also known as the "Interest Coverage Ratio."
Times interest earned is a key metric to determine the credit worthiness of a business. Essentially, the number represents how many times the last 12 months' EBIT (earnings before interest and taxes) would have covered the past 12 months' interest expenses.
This ratio works well when looking at manufacturing businesses, utilities, and certain service businesses. It should be used with care when analyzing financial service companies because their business models borrow differently from traditional manufacturing and service businesses.
Learn More
You may also be interested in these HEB related companies
HEB News
$HEB maybe Carter can put Ampligen in e-cigarettes now that it's 2012 since he already explored putting it in real cigarettes in the 1980's
about 22 days ago by HankHill
about 22 days ago by HankHill
Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2012
May 07, 4:35PM GlobeNewswire
May 07, 4:35PM GlobeNewswire
$heb ever hold a stock so you could laugh at it every day ? i have
about 40 days ago by roadkingtrdr
about 40 days ago by roadkingtrdr
Hemispherx Biopharma, Inc. to Host 2011 Year End Conference Call on Thursday, March 22, 2012
Mar 20, 8:30AM GlobeNewswire
Mar 20, 8:30AM GlobeNewswire
$HEB Cross over coming also a Triple top breakout at stockcharts.com on the P&F.
about 71 days ago by rtk
about 71 days ago by rtk
Hemispherx Publishes Data on the Bioactivity of Ampligen(R) in Chronic Fatigue Syndrome ("CFS")
Mar 19, 8:30AM GlobeNewswire
Mar 19, 8:30AM GlobeNewswire
$HEB , I am early but bot it this morning. loking for a nice pop
about 116 days ago by 3DTRADINGTRADER
about 116 days ago by 3DTRADINGTRADER
Hemispherx Biopharma Receives U.S. Patent Office Notification of Two New Patents Granted for Alferon(R) LDO
Jan 17, 8:30AM GlobeNewswire
Jan 17, 8:30AM GlobeNewswire
Hemispherx Biopharma (HEB) Recieves FDA Extension for NDA for Treatment of Chronic Fatigue Syndrome
Jan 11, 8:35AM Street Insider
Jan 11, 8:35AM Street Insider
$HEB shares up 14% following extension to modify NDA for treatment of CFS
about 139 days ago by Street_Insider
about 139 days ago by Street_Insider
Hemispherx Biopharma (HEB) Gets Extension from FDA for CFS NDA Modification
Jan 11, 8:31AM Street Insider
Jan 11, 8:31AM Street Insider
FDA Grants $HEB Extension in Its Pending New Drug Application for the Treatment of Chronic Fatigue
about 139 days ago by Benzinga
about 139 days ago by Benzinga
Hemispherx Biopharma Announces Further Adjournment on Proposal Number 4 From the 2011 Annual Meeting of Stockholders
Nov 09, 4:13PM GlobeNewswire
Nov 09, 4:13PM GlobeNewswire
Hemispherx Biopharma Announces Financial Results for the Three Months Ended September 30, 2011
Nov 09, 12:26PM GlobeNewswire
Nov 09, 12:26PM GlobeNewswire
Hemispherx Biopharma, Inc. to Host Conference Call on Chronic Fatigue Syndrome Progress Thursday, October 27, 2011
Oct 24, 10:22AM GlobeNewswire
Oct 24, 10:22AM GlobeNewswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| HEB | 0.28 | +0.01 | +3.70% | 36.67M |
| ISIL | 10.84 | +0.40 | +3.83% | 1.322B |
| ISIG | 1.90 | +0.01 | +0.53% | 25.70M |
| ISI | 60.05 | -0.10 | -0.17% | |
| ISH | 18.35 | +0.25 | +1.38% | 130.68M |
| ISCA | 23.99 | +0.54 | +2.30% | 1.085B |
| IPSU | 6.34 | -0.01 | -0.16% | 77.60M |
| IPS | 31.32 | +0.04 | +0.13% | |
| IPN | 22.70 | -0.20 | -0.87% | |
| IPK | 22.62 | +0.14 | +0.62% |
